Trials / Completed
CompletedNCT00684710
Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects
Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of PAZ-417 after administration of ascending single oral doses to healthy young Japanese male and healthy elderly Japanese male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PAZ-417 | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2008-05-28
- Last updated
- 2009-01-30
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00684710. Inclusion in this directory is not an endorsement.